Human platelet lysate as a replacement for fetal bovine serum in human corneal stromal keratocyte and fibroblast culture

Nina Seidelmann1 | Daniela F. Duarte Campos2,3 | Malena Rohde1 | Sandra Johnen1 | Sabine Salla1,4 | Gary Hin-Fai Yam5,6 | Jodhbir S. Mehta6,7,8,9 | Peter Walter1,4 | Matthias Fuest1

Abstract
The isolation and propagation of primary human corneal stromal keratocytes (CSK) are crucial for cellular research and corneal tissue engineering. However, this delicate cell type easily transforms into stromal fibroblasts (SF) and scar inducing myofibroblasts (Myo-SF). Current protocols mainly rely on xenogeneic fetal bovine serum (FBS). Human platelet lysate (hPL) could be a viable, potentially autologous, alternative. We found high cell survival with both supplements in CSK and SF. Cell numbers and Ki67+ ratios increased with higher fractions of hPL and FBS in CSK and SF. We detected a loss in CSK marker expression (Col8A2, ALDH3A1 and LUM) with increasing fractions of FBS and hPL in CSK and SF. The expression of the Myo-SF marker SMA increased with higher amounts of FBS but decreased with incremental hPL substitution in both cell types, implying an antifibrotic effect of hPL. Immunohistochemistry confirmed the RT-PCR findings. bFGF and HGF were only found in hPL and could be responsible for suppressing the Myo-SF conversion. Considering all findings, we propose 0.5% hPL as a suitable substitution in CSK culture, as this xeno-free component efficiently preserved CSK characteristics, with non-inferiority in terms of cell viability, cell number and proliferation in comparison to the established 0.5% FBS protocol.

KEYWORDS
cell culture, cornea, keratocyte

1Department of Ophthalmology, RWTH Aachen University, Aachen, Germany
2Institute of Applied Medical Engineering, RWTH Aachen University Hospital, Aachen, Germany
3Center for Molecular Biology, Heidelberg University, Heidelberg, Germany
4Cornea Bank Aachen, RWTH Aachen University, Aachen, Germany
5Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
6Tissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore, Singapore
7Singapore National Eye Centre, Singapore, Singapore
8Eye-Academic Clinical Program, Duke-National University of Singapore (NUS) Graduate Medical School, Singapore, Singapore
9School of Material Science and Engineering, Nanyang Technological University, Singapore, Singapore

Correspondence
Matthias Fuest, Department of Ophthalmology, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany.
Email: mfuest@ukaachen.de

Funding information
Deutsche Ophthalmologische Gesellschaft

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
INTRODUCTION

The ex vivo cultivation of primary human corneal stromal kerocytes (CSK) and stromal fibroblasts (SF) is crucial for corneal research and treatment.1–4

Corneal transplantation is the current treatment modality of choice for patients with advanced corneal disease to revive visual ability.1,5 However, many factors restrict the long-term success including limited graft survival, allogeneic graft rejection, the need for immunosuppressants, high associated costs and most importantly the global donor material shortage.1,6

Recent years have seen increasing interest in understanding corneal disease and the implication of cells of the corneal stroma.3,7 In addition, efforts have been undertaken in the search for tissue-engineered alternatives to human donor corneal transplants.2,8

Corneal cell therapy has seen great advances, particularly for the epithelial and endothelial layers.1,6,9,10 Nevertheless, the targeted delivery of cells into the cornea to treat stromal disease, which could possibly replace corneal transplantation for some indications in the future, is still in its beginnings.1,4,11,12

When carefully inspecting the published literature on experiments with human cells of the corneal stroma, it is easily recognized that in the majority of studies SF were used for experiments,13,14 while very few studies verified the true CSK character of cells before use.3,15,16

The isolation and propagation of CSK are challenging, as this delicate cell type easily transforms into scar inducing SF and α-smooth muscle actin (SMA) expressing myofibroblasts (Myo-SF).17 CSK differ fundamentally from SF, for example in terms of phenotype, gene expression, transparency, extracellular matrix (ECM) remodelling and neuroregulatory capabilities.3,15,16 Therefore, expanding human CSK, SF and Myo-SF ex vivo, while maintaining their unique phenotype, is imperative and extremely desirable for cell research, understanding corneal disease and wound healing as well as their possible future application in tissue-engineering and cell therapy.1–4

Yam et al.17 recently introduced a protocol to safely propagate CSK ex vivo. In their protocol, primary human CSK are “activated” by culturing them with very low fetal bovine serum additive (0.5% FBS), which allows expansion for 6–8 passages ex vivo. When the activated CSK are then returned to serum-free culture, CSK characteristics become reinforced.17

Concerns have been raised regarding the safety of FBS-based culture media. Bovine antigens, for instance, accumulate intracellularly; hence, cells expanded in FBS containing medium can lead to anaphylactic reactions if administered repeatedly.18–21 The ingredients of FBS are not precisely defined, and there is a high lot-to-lot variation.22

Fetal bovine serum can contain high endotoxin levels, potentially increasing the production of proinflammatory and profibrogenic cytokines in cultured cells.22,23 Additionally, the bleeding procedure of bovine fetuses, necessary for FBS production, is of animal welfare concern.22 Therefore, protocols to culture cells for clinical applications should—according to Good Manufacturing Practice—avoid the usage of animal sera.24

Over the last decade, different preparations of human blood products have been tested regarding their suitability as xeno-free cell culture additives to replace FBS, among them plasma rich in growth factors (PRGF), platelet-rich plasma (PRP) and human plasma lyase (hPL).25 To date, there are no standardized protocols, which entails heterogeneity in terms of nomenclature, manufacturing and content.25

However, the production of all these products involves the separation of blood components from platelets and plasma by centrifugation as well as releasing a wide range of growth factors from platelets by cell activation and/or lysis steps. Platelets contain more than 1,100 different proteins, among them transforming growth factor β (TGF-β), platelet-derived growth factor (PDGF), insulin-like growth factor 1 (IGF-1), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and others, which are known to be involved in tissue regeneration.26,27

Nevertheless, some limitations remain. Depending on the protocol, studies have shown that PRP contained higher amounts of leukocytes than PRGF,28 which is known to have a negative effect on cell viability.29 Previous protocols used bovine thrombin to activate platelets during PRP production, which incurs the risk of immunogenic reactions. Activation by calcium chloride is a viable alternative.26 hPL on the other hand is usually generated by a freeze-thaw procedure of platelet concentrates, which is fast and effective and lyse all corpuscular elements. This leads to a very high growth factor content and low leukocyte concentrations in hPL.22,25,29

Plasma rich in growth factor and PRP are usually prepared on site using specialized kits.7 Pooled allogenic hPL, used in this study, is commercially available, allowing improved growth factor control and consistency.25,30 In addition, hPL is habitually stored frozen and easily used for consecutive applications.25 It should be noted that several groups freeze their PRP or PRGF before addition to culture medium, which then closely resembles hPL. PRGF, PRP and hPL can all be used in autologous settings to further reduce risks of contamination or immune reactions.22

Previous research has shown promising effects of hPL on cells of the eye. hPL enhanced the proliferation of human mesenchymal stem cells (hMSC) and conjunctival fibroblasts.31,32 In a clinical trial, hPL eye drops led to the uncomplicated healing of various corneal lesions.33

In summary, there is significant evidence promoting a beneficial effect of hPL vs. FBS for human CSK and SF culture, which we investigated in this study.

MATERIALS AND METHODS

2.1 Isolation of CSK and SF

Human CSK were isolated from 22 corneas (11 donors) unsuitable for transplantation (age 64.6 ± 14.6 years, male = 6, female = 5) supplied by the Cornea Bank Aachen, following institutional review board approval (EK 291/20). CSK were isolated and cultivated as previously described.8,15,17 Briefly, corneas were washed with sterile phosphate-buffered saline.
TABLE 1 Medium composition for experimental human corneal stromal keratocyte (CSK) and stromal fibroblast (SF) culture substituted with fetal bovine serum (FBS) or human platelet lysate (hPL)

| Medium | CSK medium | SF medium |
|--------|------------|-----------|
| Basal medium | DMEM/ Ham’s F12 (Merck) + 1% MEM nonessential amino acids (Gibco) + 0.8% Penicillin-Streptomycin (Sigma-Aldrich) + 1% Amphotericin B (Sigma-Aldrich) + 0.004% Heparin (5000 U/ml, PL Bioscience) | DMEM/ Ham’s F12 + 1% MEM nonessential amino acids + 0.8% Penicillin-Streptomycin + 1% Amphotericin B |
| 0.5% FBS | + 0.5% FBS (Panbiotech) | + 0.5% FBS |
| 5% FBS | + 5% FBS | + 5% FBS |
| 0.5% hPL | + 0.5% hPL (PL Bioscience) + 0.0002% Heparin (5000 U/ml, PL Bioscience) | + 0.5% hPL + 0.0002% Heparin |
| 2% hPL | + 2% hPL + 0.0008% Heparin | + 2% hPL + 0.0008% Heparin |
| 10% hPL | + 10% hPL + 0.004% Heparin | + 10% hPL + 0.004% Heparin |

(PBS, 0.1 M; Merck KGaA), the central button was trephined (8.0 mm diameter) and incubated with dispase II (20 mg/ml; Roche) for 1 h at 37°C. The loosened corneal epithelium and endothelium were removed by gentle scraping. The remaining stromal tissue was then digested with collagenase I (1.5 µg/ml; Gibco, Life Technologies) in CSK basal medium (Table 1) for 12 h at 37°C. Single cells were then suspended in CSK basal medium with 0.5% FBS (Panbiotech), Cells were seeded on collagen-I-coated (type I collagen, solution from rat tail, Sigma-Aldrich) culture plates (BD Biosciences). The medium was changed every 3 days. Cells were passaged 1:2 when they reached 70%-80% confluence using trypsin-EDTA (0.05%; Gibco).

2.2 | Cell culture of CSK and SF

Corneal stromal keratocytes were cultured in CSK basal medium containing 0.5% FBS until passage 3 (Figure 1). After washing three times with PBS, CSK were incubated for 24 h in serum-free basal medium. After 24 h, the medium was exchanged for new medium containing the according substitutes (Table 1). In media containing hPL (PL Bioscience), 2 IU/ml heparin (PL Bioscience) was added according to the manufacturer’s instructions to avoid gel formation. The 0.5% FBS CSK group served as control. At passage 3, CSK from each cornea were also converted into SF by incubating them for 7 days in SF basal medium substituted with 5% FBS. After washing in PBS for three times and 24 h in serum-free medium, SF were also exposed to the five different media (Table 1). After 3 days of culture in the according substitutes, cells were harvested for further testing.

2.3 | Viability and cell number analysis

Cells were seeded at 9000 cells/1.8 cm² on collagen-I-coated 4-well chamber slides (Nunc Labtek Chamber Slide, Sigma-Aldrich) and incubated in different media (Table 1) for 3 days at 37°C. Then, the media were removed and 5% fluorescein diacetate (FDA) and 5% propidium iodide (PI) in PBS (both from Sigma-Aldrich) added for live/dead staining. Cells incubated in media with 50% DMSO (Applichem) for 15 min to live/dead staining served as a negative control. Samples were imaged by fluorescence microscopy (Leica DM6000B microscope, Leica Microsystems GmbH). The number and percentage of live (green fluorescence) and dead cells (red fluorescence) was quantified in 10 random fields per well using cell counter plugin for Image J (Wayne Rasband). For the evaluation of cell growth, cell numbers after 3 days of culture were compared to the seeding density. Experiments were done in triplicate for eight donors.

2.4 | Immunohistochemistry

Cells were seeded at 10,000 cells/2.0 cm² on collagen-I-coated glass cover slips (VWR International). After 3 days of culture in different media (Table 1), cells were fixed with neutral-buffered 4% paraformaldehyde (Sigma-Aldrich). After quenching with ice-cold 50 mM ammonium chloride (Sigma-Aldrich), samples were washed with PBS containing 0.2% bovine serum albumin (BSA; Sigma-Aldrich) and blocked with 1% bovine serum albumin and Triton X (1 µl/ml; Sigma-Aldrich) followed by incubation with primary antibodies for 2 h at room temperature (CSK markers: rabbit anti-ALDH3A1; 1:200, Invitrogen), rabbit anti-lumican (1:100, Invitrogen); Myo-SF marker: mouse anti-SMA1 (1:200, Invitrogen); proliferation marker: rabbit anti-Ki67 (1:200, Abcam). After buffer washes, samples were incubated with the respective secondary antibodies conjugated with Alexa Fluor 488 (goat anti-rabbit, 1:2000, Invitrogen) or Alexa Fluor 555 (donkey anti-mouse, 1:2000, Invitrogen) for 1 h. The samples were buffer-washed, mounted with Prolong Gold antifader reagent with DAPI (Invitrogen) for nuclear staining.
contrast staining and visualized by fluorescence microscopy (Leica DM6000B microscope, Leica Microsystems GmbH) and Diskus Viewer 4.8 (Hilgers Technisches Büro e. K.). To quantify cell proliferation, the Ki67+ fraction was counted in 10 random fields per slide using cell counter plugin for Image J. 34 Experiments were done in triplicate for eight donors.

2.5 | Real-time polymerase chain reaction

Cells were seeded at 47,000 cells/9.5 cm² on collagen-I-coated 6-well plates (Corning, New York, USA) and incubated in different media (Table 1) for 3 days at 37°C. Total RNA from cultured cells was extracted using RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. Reverse transcription was carried out with the Reverse Transcription System (Promega). Alterations in gene expression were analysed by quantitative real-time PCR (RT-PCR) using the LightCycler FastStart DNA Master SYBR Green I kit (Roche) with the LightCycler 1.2 (Roche). Samples were run in duplicate using the following primers (Table S1): glyceraldehyde-3-phosphate dehydrogenase (GAPDH), aldehyde dehydrogenase family 3 member A1 (ALDH3A1), collagen 8A2 (Col8A2), lumican (LUM) and α-smooth muscle actin (SMA). Relative fold changes in gene expression were analysed using the comparative CT (2−ΔΔCt) method for 10 different donors. 35 Relative fold changes were calculated to the reference of CSK 0.5% FBS.

2.6 | Quantification of growth factors in FBS and hPL

Enzyme-linked immunosorbent assays (ELISA) were performed according to the manufacturer’s protocol to determine the amount of basic fibroblast growth factor (bFGF; RayBio Human bFGF ELISA Kit; RayBiotech), hepatocyte growth factor (HGF; RayBio Human HGF ELISA Kit; RayBiotech) and TGF-β1 (EIA Kit; Enzo Life Sciences) in our FBS and hPL. Tests were run in triplicate and serial dilutions for five different batches of FBS and hPL.

2.7 | Statistical analysis

All data were expressed as mean ± standard deviation (SD). Statistical analyses were performed with SPSS version 22.0 (IBM). Mann-Whitney U or Wilcoxon rank-sum tests were used to compare cell viability, cell numbers, proliferation rates, gene ratios and growth factor levels. A p value ≤0.05 was considered statistically significant.
3 | RESULTS

3.1 | Viability and cell morphology analysis

Viability analysis of CSK via FDA/PI staining showed high viability rates in all groups and containment of typical dendritic morphology in 0.5% FBS, 0.5% and 2% hPL (Figure 2A). 5% FBS CSK showed a fibroblastic appearance, and 10% hPL led to a spider web-like arrangement of CSK. Viability rates of CSK 0.5% hPL (99.56 ± 0.31%, p = 0.010), 2% hPL (99.65 ± 0.46%, p = 0.012) and CSK 10% hPL (99.77 ± 0.388%, p = 0.001) were significantly higher compared to the reference of CSK 0.5% FBS (98.49 ± 0.89%; Figure 3A, Table S2).

Stromal fibroblasts showed high viability in all tested groups without significant differences (Figures 2B and 3A, Table S3). 10% hPL SF also showed a spider web-like arrangement of cells.

3.2 | Cell number and proliferation analysis

Corneal stromal keratocytes showed significantly higher cell numbers after 3 days of incubation in media containing 2% hPL (156.8 ± 48.7/mm², p = 0.011; Figure 3B, Table S2) and 10% hPL (168.1 ± 52.6/mm², p = 0.004), compared to the CSK 0.5% FBS (75.9 ± 20.0/mm²) control. The other groups did not differ significantly from the reference.

Cell numbers were significantly higher in SF 10% hPL (233.4 ± 71.8, p = 0.009, Figure 3B, Table S3) compared to the SF 0.5% FBS (106.9 ± 45.3) control group. Cell numbers of SF 5% FBS, SF 0.5% hPL and SF 2% hPL showed no significant difference compared to the control.

For CSK, the Ki67+ fraction did not differ between CSK 0.5% hPL (18.21 ± 6.51%, p = 0.327, Figure 3C and 4A fourth row), Table S2) and the CSK 0.5% FBS control (11.18 ± 6.08%). In all other CSK groups the Ki67+ fraction was significantly higher compared to the control.

For SF, the Ki67+ fraction was significantly higher in all groups compared to SF 0.5% FBS (SF 5% FBS [49.59 ± 1.38%, p = 0.024], SF 2% hPL [62.77 ± 4.31%, p = 0.012] SF 10% hPL [66.61 ± 2.68%, p < 0.001]), apart from SF 0.5% hPL (43.42 ± 2.27%, p = 0.911 Figure 3C and 4B fourth row), Table S3).

3.3 | Immunohistochemistry

Corneal stromal keratocytes showed a positive expression of LUM in CSK 0.5% FBS, 0.5% hPL and 2% hPL. LUM was poorly expressed in CSK 5% FBS and 10% hPL (Figure 4A, second row).

No SMA expression was detected in any CSK group (Figure 4A, second row).

ALDH3A1 was highly expressed in CSK 0.5% FBS and in 0.5% hPL. Low expression was seen in 2% hPL. In CSK 5% FBS and 10% hPL no expression of ALDH3A1 was detected (Figure 4A, third row).

Immunohistochemistry staining of SF showed a weak expression of LUM in SF 0.5% FBS, SF 0.5% hPL and SF 2% hPL. No expression was seen in SF 5% FBS and SF 10% hPL (Figure 4B, top row).
α-Smooth muscle actin staining revealed a strong expression in SF 5% FBS, a weaker expression in SF 0.5% FBS and 0.5% hPL, marginal expression in 2% hPL and no staining in 10% hPL (Figure 4B, second row).

ALDH3A1 was weakly expressed in SF 0.5% FBS and SF 0.5% hPL. No expression was seen in SF 5% FBS, SF 2% hPL and SF 10% hPL (Figure 4B, third row).

3.4 | RT-PCR

SF induction

Corneal stromal keratocytes were transformed to SF by culturing them for 7 days in 5% FBS medium. The transformation was verified by comparing the relative gene expression between CSK 0.5% FBS and the SF. SF showed a significant decrease in the expression of CSK markers ALDH3A1 (0.37 ± 0.11, p = 0.020, Figure 5, Table S2), LUM (0.11 ± 0.03, p = 0.007) and Col8A2 (0.488 ± 0.426, p = 0.027) and a significant increase in the Myo-SF marker SMA (4.29 ± 1.14, p = 0.010).

Effects of hPL and FBS on CSK

Comparing the relative gene expression of 0.5% FBS CSK to the rest of the CSK group, the CSK markers Col8A2 and ALDH3A1 were significantly decreased in CSK 5% FBS (Col8A2: 0.36 ± 0.26, p = 0.006, ALDH3A1: 0.14 ± 0.09, p < 0.001, Figure 6, Table S2), CSK 2% hPL (Col8A2: 0.20 ± 0.20, p = 0.001, ALDH3A1: 0.16 ± 0.12, p < 0.001) and CSK 10% hPL (Col8A2: 0.19 ± 0.11, p = 0.001, ALDH3A1: 0.21 ± 0.19, p < 0.001). No significant differences were seen between CSK 0.5% hPL (Col8A2: 0.90 ± 0.53, p = 0.745, ALDH3A1: 1.15 ± 0.55, p = 0.527) and CSK 0.5% FBS (Col8A2: 1.00 ± 0.425, ALDH3A1: 1.00 ± 0.38).

Lumican expression was significantly decreased in CSK 5% FBS (0.10 ± 0.04, p < 0.001), CSK 2% hPL (0.44 ± 0.24, p = 0.007) and CSK 10% hPL (0.09 ± 0.09, p < 0.001) compared to the CSK 0.5% FBS control (1.00 ± 0.39). No significant differences were seen between CSK 0.5% hPL (1.21 ± 0.47, p = 0.339) and CSK 0.5% FBS (1.00 ± 0.39).

An increased SMA expression was detected in CSK 5% FBS (1.74 ± 0.36, p = 0.003). No significant differences occurred between CSK 0.5% FBS, CSK 0.5% hPL and CSK 2% hPL. CSK 10% hPL had a significantly lower SMA expression (0.66 ± 0.16, p = 0.014).

Marker expression of SF compared to CSK

Comparing the relative gene expression of the SF group to 0.5% FBS CSK, a significantly lower expression of Col8A2 and ALDH3A1 was detected in all SF apart from SF 0.5% hPL (Col8A2: 0.58 ± 0.56, p = 0.112, ALDH3A1: 0.78 ± 0.19, p = 0.127; Figure 6, Table S3). All SF groups showed a significantly lower expression of LUM in comparison to the 0.5% FBS CSK control. Expression of SMA was significantly elevated in all SF groups except for SF 10% hPL (1.16 ± 0.38, p = 0.332) in comparison to the 0.5% FBS CSK control.

3.5 | ELISA

Via ELISA a bFGF content of 0.067 ± 0.017 ng/ml was found in our hPL solutions. In our FBS solutions bFGF was not detectable (Table 2). The HGF content of our hPL solutions was 1.074 ± 0.050 ng/ml. HGF was not detectable in our FBS solutions. The amount of TGF-β1 was significantly higher in our hPL (1.861 ± 0.231 ng/ml, p < 0.001) compared to our FBS solutions (0.015 ± 0.010 ng/ml).

4 | DISCUSSION

In this study, we investigated the suitability of hPL as a replacement for FBS for the xeno-free culture of primary human CSK and SF. We
reliably induced SF conversion by incubating CSK for 7 days in 5% FBS medium, which decreased CSK marker expression and induced SMA. We found a high survival (98%–100%) with both supplements in CSK and SF. Cell numbers and Ki67+ ratios increased with higher fractions of hPL and FBS in CSK and SF. We detected a loss in CSK marker expression (ALDH3A1, LUM and Col8A2) with higher fractions of FBS and hPL in CSK and SF. The expression of the Myo-SF marker SMA increased with larger amounts of FBS but decreased with incremental hPL substitution in both cell types, implying an antifibrotic effect of hPL. Immunohistochemistry confirmed the RT-PCR findings. bFGF and HGF were only found in our hPL and could be responsible for suppressing the Myo-SF conversion.

For SF induction we incubated CSK in media containing 5% FBS for 7 days. Reliable SF conversion with this protocol has been shown before by Yam et al.3

Unfortunately, there is no characteristic marker for corneal SF, as for example CSK (ie ALDH3A1, LUM, Col8A2).15,17,26 Collagen VIII (Col8) in context of the cornea is usually associated with the Descemet membrane and corneal endothelial cells/disease.37 Nevertheless, Col8 is also expressed in the central corneal stroma,38 and Col8A2 by CSK.39 We previously demonstrated, that Col8A2 expression is higher in CSK than in SF, and can be used to differentiate between the two.17

The conversion of CSK to SF is usually described by a loss of typical CSK markers, and the expression of unspecific fibroblastic cell markers such as Thy-1 membrane glycoprotein (Thy-1/CD90), fibronectin or tenascin C.11,14,36,40–42 Stimulated by TGF-β1, corneal SF can further transform to SMA expressing Myo-SF, one of the most important processes in corneal fibrosis (scarring).43,44 The biological effects of TGF-β1 in the cornea have been shown to follow SMAD-dependent as well as SMAD-independent signalling pathways depending upon cellular responses and microenvironments.45 The complex process of corneal scarring to date is still not fully understood.45 In this study, we confirmed Myo-SF induction via elevation of SMA expression and loss of the CSK markers LUM, ALDH3A1 and Col8A2.
Overall, we found very high viability rates for SF and CSK in hPL and FBS after a culture period of 3 days, indicating no toxicity of these components.

This is the first study investigating the effect of hPL on the cell viability of human CSK and SF. However, hPL has proven to support viability in other corneal cell lines.

Thieme et al. used 5% FBS and 0.02% hPL for the expansion of primary human corneal endothelial cells. With a colorimetric metabolic activity assay, they found comparable viabilities in both groups for incubation times up to 25 days.46

Brejchova et al.47 detected similar quantities of apoptotic cells (1%–3%; TUNEL) in primary human limbal epithelial cells cultured in either 10% hPL or 10% FBS substituted media for 2–4 weeks.

In our study, cell numbers and proliferation rates of SF and CSK increased with higher fractions of hPL and FBS.

For primary human CSK, Yam et al. found a mitotic index (MI) of 0.6 ± 0.5% in 0.5% FBS, as well as 2.4 ± 1.6% in 2% FBS at 6 days of culture.17 In agreement, we also found higher CSK Ki67+ rates in 5% FBS (35.29 ± 5.95%) compared to 0.5% FBS (11.18 ± 6.08%) after 3 days of culture. Ki67 is a nuclear proliferation factor expressed at all stages of the cell cycle except G0.48 Therefore, Ki67+ fractions are generally higher than the MI; however, the difference varies depending on cell type.49–51

Lilienesik et al.52 incubated primary human SF in 10% FBS for a period of 5 days. They found an increment in cell number of 235%–258%. We saw an increment in our SF population in 5% FBS of ~270% over 3 days of culture. We deliberately seeded our cells at a density that enabled free proliferation. Lilienesik et al.52 used a seeding density twice as high as our seeding density, which could have caused contact inhibition. In addition they used primary human stromal cells for their experiments straight after isolation, which were most likely closer to a CSK than SF phenotype and CSK proliferate slower even in 5% FBS, which we also saw in our experiments.

This is the first study investigating the influence of different fractions of hPL on the proliferation of primary human CSK and SF.

Mathyssen et al. examined the population doubling time of hMSC derived from the corneal stroma incubated in media supplemented with 2.5% hPL, 5% hPL and 10% hPL or 2.5% FBS, 5% FBS and 10% FBS. Doubling times decreased with elevated fractions of hPL and FBS, which is consistent with our findings. Mathyssen et al.53 found that 10% hPL induced the shortest doubling times of all. Similarly, our cell numbers were the highest with 10% hPL. However, we did not investigate 10% FBS and CSK, being mature cells, differ substantially from hMSC, which demonstrated osteogenic, chondrogenic and adipogenic capacity in this study.53 FBS and hPL are rich in growth factors, but hPL is inherently richer in growth factors from the platelet fraction, which are known to enhance cell proliferation.22 This explains higher cell proliferation in hPL than in respective amounts of FBS.

**Figure 5** Comparison of gene expression by RT-PCR for aldehyde dehydrogenase family 3 member A1 (ALDH3A1), collagen 8A2 (Col8A2), lumican (LUM) and α-smooth muscle actin (SMA) of corneal stromal keratocytes (CSK) in 0.5% FBS compared to stromal fibroblasts (SF) incubated in 5% FBS for 7 days. Gene ratios are shown as relative fold changes to the CSK 0.5% FBS control. Differences are indicated by *p ≤ 0.05, **p ≤ 0.01

**Figure 6** Comparison of gene expression by RT-PCR for aldehyde dehydrogenase family 3 member A1 (ALDH3A1), collagen 8A2 (Col8A2), lumican (LUM) and α-smooth muscle actin (SMA) in corneal stromal keratocytes (CSK) and stromal fibroblasts (SF) after incubation in media supplemented with 0.5% fetal bovine serum (FBS), 5% FBS, 0.5% human platelet lysate (hPL), 2% hPL and 10% hPL for 3 days. Differences were compared to the reference of 0.5% FBS CSK (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001)
| Growth factor levels in our FBS solutions measured by ELISA | Growth factor levels in our hPL solutions measured by ELISA | Growth factor levels in FBS in literature | Growth factor levels in hPL in literature | Growth factor levels of hPL in literature | Growth factor levels of FBS in literature |
|----------------------------------------------------------|---------------------------------------------------------|----------------------------------------|----------------------------------------|---------------------------------------|----------------------------------------|
| 1.861 ± 0.231 ng/ml                                       | 0.015 ± 0.01 ng/ml                                       | 1.861 ± 0.231 ng/ml                   | 0.015 ± 0.01 ng/ml                     | 50.838 ± 5.553 ng/ml                 | 1.071 ± 0.050 ng/ml                     |
| 6.210 ± 1.147 ng/ml                                       | 0.015 ± 0.01 ng/ml                                       | 6.210 ± 1.147 ng/ml                   | 0.015 ± 0.01 ng/ml                     | 74.200 ± 0.000 ng/ml                 | 1.071 ± 0.050 ng/ml                     |
| Detectable                                               | Determinable                                            | 1.071 ± 0.050 ng/ml                   | 0.015 ± 0.01 ng/ml                     | 14.134 ± 0.142 ng/ml                 | Not detectable                          |
| 0.067 ± 0.017 ng/ml                                       | 0.067 ± 0.017 ng/ml                                       | 0.064 ± 0.009 ng/ml                   | 0.064 ± 0.009 ng/ml                    | 0.064 ± 0.009 ng/ml                 | Not detectable                          |
| 0.029 ± 0.003 ng/ml                                       | 0.029 ± 0.003 ng/ml                                       | 0.092 ± 0.036 ng/ml                   | 0.092 ± 0.036 ng/ml                    | 0.092 ± 0.036 ng/ml                 | Not detectable                          |
| 0.067 ± 0.017 ng/ml                                       | 0.067 ± 0.017 ng/ml                                       | 2.147 ± 0.014 ng/ml                   | 2.147 ± 0.014 ng/ml                    | 2.147 ± 0.014 ng/ml                 | Not detectable                          |
| Detectable                                               | 0.064 ± 0.009 ng/ml                                       | 0.033 ± 0.010 ng/ml                   | 0.033 ± 0.010 ng/ml                    | 0.033 ± 0.010 ng/ml                 | Not detectable                          |
| 0.092 ± 0.017 ng/ml                                       | 0.092 ± 0.017 ng/ml                                       | 1.071 ± 0.050 ng/ml                   | 1.071 ± 0.050 ng/ml                    | 1.071 ± 0.050 ng/ml                 | Not detectable                          |
| 0.092 ± 0.017 ng/ml                                       | 0.092 ± 0.017 ng/ml                                       | 0.190 ± 0.014 ng/ml                   | 0.190 ± 0.014 ng/ml                    | 0.190 ± 0.014 ng/ml                 | Not detectable                          |
| 1.147 ± 0.025 ng/ml                                       | 1.147 ± 0.025 ng/ml                                       | 1.960 ± 1.360 ng/ml                   | 1.960 ± 1.360 ng/ml                    | 1.960 ± 1.360 ng/ml                 | Not detectable                          |
| Not detectable                                           | 0.067 ± 0.017 ng/ml                                       | 14.134 ± 0.142 ng/ml                 | 14.134 ± 0.142 ng/ml                   | 14.134 ± 0.142 ng/ml                 | Not detectable                          |
| 1-100 ng/ml                                              | 1-100 ng/ml                                              | 0.000 ng/ml                           | 0.000 ng/ml                           | 0.000 ng/ml                           | Not detectable                          |
| 50-300 ng/ml                                             | 50-300 ng/ml                                             | 0.000 ng/ml                           | 0.000 ng/ml                           | 0.000 ng/ml                           | Not detectable                          |
and FBS, evaluate the content in HGF, nor did they evaluate the alterations in typical CSK markers.

Nevertheless, our findings are limited by the high lot-to-lot variation in FBS and hPL supplements (Table 2). Future studies are needed to replicate our findings with other hPL/FBS sources. In addition, the possible antifibrotic effect of hPL needs to undergo further extensive verification in different cell and animal models.

The fate of SF and particularly Myo-SF after corneal wound healing remains controversial with differences between in vivo and in vitro studies. In vivo, the development of mature vimentin+, SMA+ desmin−(VAD−) corneal Myo-SF in rabbits after epithelial-stromal injury took two to four weeks. In humans, this development is believed to take one to four months, based on the time until visible scarring after corneal lacerations or high-correction photorefractive keratectomy. Once the basement membranes (BMs) are fully regenerated, TGF-β and PDGF entry into the corneal stroma decreases and the mature Myo-SF, that are dependent on ongoing sufficient levels of TGF-β, are believed to undergo apoptosis. As introduced previously human CSK seems highly improbable. As introduced by Yam et al. in 2015, primary human CSK can be propagated for six to eight passages ex vivo in a state referred to as “activated keratocytes” with very low (0.5%) FBS substitution, when returned to serum-free culture CSK-specific gene marker expression increased and morphology became more dendritic. Hence, to date, the expansion of CSK in culture has only been demonstrated with very low FBS or hPL substitution (this study). When CSK are incubated with higher levels of FBS/hPL, they turn into SF and lose their CSK characteristics. As we demonstrated, even if they are transferred to very low FBS/hPL culture, SF do not return to CSK in terms of cell morphology and marker expression. Nevertheless, further studies are needed to evaluate the possibility of re-differentiation between the different stages of human corneal stromal cells in vitro and particularly in vivo and to further characterize these cells. Blood-derived products are of high interest for this question as they seem to contain crucial factors inhibiting myo-differentiation, such as FGF or HGF.

Interestingly, 3 days of culture in 10% hPL let to a spider web-like arrangement of cells, which has not been described before during the culture of CSK or SF with blood products. In a previous project, Anitua et al. induced SF to Myo-SF with TGF-β1 stimulation, and showed that incubation in 20% PRGF for 3 days could reverse the SMA expression. While the DAPI staining is not ideal, these cells (Figure 5C, two columns to the right) resemble the spider web-like arrangement of CSK and SF in 10% hPL, we detected. In a follow-up study, Anitua et al. incubated human SF and conjunctival fibroblasts with 20% PRGF for 72 h. The recorded images do not show cells in a spider web-like arrangement; however, the utilized seeding densities and image scales could disguise such cell behaviour. Interestingly, they found residual desmin and vimentin expression in 20% PRGF cultured SF, while SMA was not detectable. This could indicate, that in high dosage blood product cell culture the non-CSK members of the cytoskeletal family are of higher importance for cell arrangement. In addition, Maltseva et al. demonstrated that in cells from rabbit corneas SMA expression in Myo-SF can be suppressed by FGF. However, FGF-heparin (20 ng/ml FGF-2) treatment for 3 days also decreased cadherin and increased connexin 43 expression. The alterations in cell-cell interaction protein expression by FGF, which is found in blood products and hPL, could be another factor leading to changes in cell arrangement in high dosage blood product cell culture. As cells in our 10% hPL groups neither expressed SMA nor CSK markers, a pure fibroblastic character is most likely. Further studies are needed to characterize the alterations to cells occurring in high dosage blood product cell culture.

Considering all findings, we found that primary human CSK and SF can be cultured with xeno-free hPL. We propose 0.5% hPL as a suitable substitution in CSK culture, as this xeno-free component efficiently preserved CSK characteristics, with non-inferiority in terms of cell viability, cell number and proliferation in comparison to the established 0.5% FBS protocol. Unfortunately, the higher proliferation rates with incremental hPL substitution came at the price of CSK marker diminution and therefore seem unsuitable for the culture of this delicate cell type. hPL contains the antifibrotic HGF and bFGF, potentially suppressing Myo-SF conversion, which could be useful in its future application in corneal cell research and treatment but requires further investigation.

ACKNOWLEDGEMENTS

This work was supported by the Deutsche Ophthalmologische Gesellschaft (DOG)/German Ophthalmology Society and the Core Facility “Immunohistochemistry” of the Interdisciplinary Center for Clinical Research (IZKF) Aachen within the Faculty of Medicine at the RWTH Aachen University. The authors thank the Cornea Bank Aachen for supplying human corneas unsuitable for transplantation.
for this study, as well as Antjie Schiefer, Anna Dobias, and Anne Freialdenhoven for assisting in the laboratory work. Open Access funding enabled and organized by Projekt DEAL.

CONFLICTS OF INTEREST
The authors have no relevant financial or non-financial interests to disclose.

AUTHOR CONTRIBUTIONS
Nina Seidelmann: Conceptualization (lead); Data curation (lead); Formal analysis (lead); Funding acquisition (lead); Investigation (lead); Methodology (lead); Project administration (lead); Resources (lead); Software (lead); Supervision (lead); Validation (lead); Visualization (lead); Writing-original draft (lead). Daniela F. Daniela Campos: Conceptualization (equal); Data curation (equal); Investigation (equal); Methodology (equal); Writing-original draft (equal). Malena Rohde: Investigation (equal); Methodology (equal); Validation (equal). Sandra Johnen: Investigation (equal); Methodology (equal); Validation (equal). Sabine Salla: Investigation (supporting); Project administration (supporting); Resources (supporting); Validation (equal). Gary Hin-Fai Yam: Conceptualization (equal); Data curation (equal); Investigation (equal); Methodology (equal); Writing-original draft (supporting). Peter Walter: Conceptualization (supporting); Funding acquisition (equal); Project administration (equal); Resources (equal); Supervision (equal). Matthias Fuest: Conceptualization (lead); Data curation (lead); Formal analysis (lead); Funding acquisition (lead); Investigation (lead); Methodology (lead); Project administration (lead); Resources (lead); Software (lead); Supervision (lead); Validation (lead); Visualization (lead); Writing-original draft (lead).

DATA AVAILABILITY STATEMENT
All data can be requested form the corresponding author.

ORCID
Gary Hin-Fai Yam https://orcid.org/0000-0002-8445-3669
Matthias Fuest https://orcid.org/0000-0002-0573-2599

REFERENCES
1. Fuest M, Yam GH, Peh GS, Mehta JS. Advances in corneal cell therapy. Regen Med. 2016;11:601-615.
2. Fuest M, Yam GH-F, Mehta JS. Duarte Campos DF. Prospects and challenges of translational corneal bioprinting. Bioengineering. 2020;7(3):71.
3. Yam G-F, Williams GP, Setiawan M, et al. Nerve regeneration by human corneal stromal keratocytes and stromal fibroblasts. Sci Rep. 2017;7:45396.
4. Yam G-F, Fuest M, Yusoff NZBM, et al. Safety and feasibility of intrastromal injection of cultivated human corneal stromal keratocytes as cell-based therapy for corneal opacities. Invest Ophthalmol Vis Sci. 2018;59:3340-3354.
5. Fuest M, Ang M, Htoon HM, Tan D, Mehta JS. Long-term visual outcomes comparing descemet stripping automated endothelial keratoplasty and penetrating keratoplasty. Am J Ophthalmol. 2017;182:62-71.
6. Fuest M, Yam GH, Peh GS, Walter P, Plange N, Mehta JS. [Corneal cell therapy-an overview]. Ophthalmologe. 2017;114:705-715.
7. Anitua E, Sanchez M, Merayo-Lloves J, De la Fuente M, Muruzabal F, Orive G. Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverses TGF-beta-induced myodifferentiation. Invest Ophthalmol Vis Sci. 2011;52:6066-6073.
8. Duarte Campos DF, Rohe M, Ross M, et al. Corneal bioprinting utilizing collagen-based bioinks and primary human keratocytes. J Biomed Mater Res A. 2019;107:1945-1953.
9. Bandeira F, Yam G-F, Fuest M, et al. Urea-de-epiteliolated human amniotic membrane for ocular surface reconstruction. Stem Cells Transl Med. 2019;8:620-626.
10. Kruse M, Walter P, Bauer B, et al. Electro-spin Membranes as scaffolds for human corneal endothelial cells. Curr Eye Res. 2018;43:1-11.
11. Hertsenberg AJ, Shojaati G, Funderburgh ML, Mann MM, Du Y, Funderburgh JL. Corneal stromal stem cells reduce corneal scarring by mediating neutrophil infiltration after wounding. PLoS One. 2017;12:e0171712.
12. El Zarif M, Alíó Del Barrio JL, Arnalich-Montiel F, De Miguel MP, Makdissy N, Alíó JL. Corneal stromal regeneration: new approach for the treatment of cornea disease. Asia Pac J Ophthalmol. 2020;9:571-579.
13. Guo X, Hutcheon AE, Melotti SA, Zieske JD, Trinkaus-Randall V, Ruberti JW. Morphologic characterization of organized extracellular matrix deposition by ascorbic acid-stimulated human corneal fibroblasts. Invest Ophthalmol Vis Sci. 2007;48:4050-4060.
14. Pei Y, Sherry DM, McDermott AM. Thy-1 distinguishes human corneal fibroblasts and myofibroblasts from keratocytes. Exp Eye Res. 2004;79:705-712.
15. Yam G-F, Teo E-W, Setiawan M, et al. Postnatal periodontal ligation as a novel adult stem cell source for regenerative corneal cell therapy. J Cell Mol Med. 2018;22:3119-3132.
16. Campos DFD, Rohe M, Yam GH-F, Mehta J, Fuest M. Corneal bioprinting utilizing collagen-based bioinks and primary human keratocytes. J Biomed Mater Res A. 2019;107(9):1945-1953.
17. Yam G-F, Yusoff NZBM, Kadaba A, et al. Ex vivo propagation of human corneal stromal “activated keratocytes” for tissue engineering. Cell Transplant. 2015;24:1849-1861.
18. Mackensens A, Drager R, Schlesier M, Mertelsmann R, Lindemann A. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother. 2000;49:152-156.
19. Gregory CA, Reyes E, Whitney MJ, Spees JL. Enhanced engraftment of mesenchymal stem cells in a cutaneous wound model by culture in allogenic species-specific serum and administration in fibrin constructs. Stem Cells. 2006;24:2232-2243.
20. Selvaggi TA, Walker RE, Fleisher TA. Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood. 1997;89:776-779.
21. Tuschong L, Soenen SL, Blaese RM, Candotti F, Muul LM. Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. Hum Gene Ther. 2002;13:1605-1610.
22. Hemeda H, Giebel B, Wagner W. Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells. Cytotherapy. 2014;16:170-180.
23. Kirikae T, Tamura H, Hashizume M, et al. Endotoxin contamination in fetal bovine serum and its influence on tumor necrosis factor production by macrophage-like cells J774.1 cultured in the presence of the serum. Int J Immunopharmacol. 1997;19:255-262.
24. Commission E. Commission directive 2003/94/EC. Off J Eur Union. 2003;46:22-26.
25. Klatt-Schulz F, Schmidt T, Uckert M, et al. Comparative analysis of different platelet lysates and platelet rich preparations to stimulate tendon cell biology: an in vitro study. *Int J Mol Sci*. 2018;19:212.

26. Rodrigues SV, Acharya AB, Thakur SL. An evaluation of platelet-rich plasma without thrombin activation with or without anorganic bone mineral in the treatment of human periodontal intrabony defects. *Platelets*. 2011;22:353-360.

27. Boswell SG, Cole BJ, Sundman EA, Karas V, Fortier LA. Platelet-rich plasma: a milieu of bioactive factors. *Arthroscopy*. 2012;28:429-439.

28. Nishiyama K, Okudera T, Watanabe T, et al. Basic characteristics of platelet-rich plasma in growth factors (PRGF): blood cell components and biological effects. *Clin Exp Dent Res*. 2016;2:96-103.

29. Doucet C, Ernou I, Zhang Y, et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. *J Cell Physiol*. 2005;205:228-236.

30. Schallmoser K, Strunk D. Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures. *J Vis Exp*. 2009;33:1523.

31. Etexbarria J, Sanz-Lázaro S, Hernández-Moya R, et al. Serum from platelet-rich growth factors regenerates rabbit corneas by promoting cell proliferation, migration, differentiation, adhesion and limb stemness. *Acta Ophthalmol*. 2017;95:e693-e705.

32. Vogel JP, Szalay K, Geiger F, Kramer M, Richter W, Kasten P. Platelet-rich plasma without thrombin activation with or without anorganic bone mineral in the treatment of human periodontal intrabony defects. *Platelets*. 2011;22:353-360.

33. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. *Nat Methods*. 2012;9:676-682.

34. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. *Nat Protoc*. 2008;3:1101-1108.

35. Funderburgh JL, Mann MM, Funderburgh ML. Keratocyte phenotype mediates proteoglycan structure: a role for fibroblasts in corneal fibrosis. *J Biol Chem*. 2003;278:45629-45637.

36. Gottsch JD, Zhang C, Sundin OH, Bell WR, Stark WJ, Green WR. Fuchs corneal dystrophy: aberrant collagen distribution in an L450W mutant of the COL8A2 gene. *Invest Ophthalmol Vis Sci*. 2005;46:4504-4511.

37. Liu Y, Huang HU, Sun G, et al. Gene expression profile of extracellular matrix and adhesion molecules in the human normal corneal stroma. *Curr Eye Res*. 2017;42:520-527.

38. Collin J, Queen R, Zerif D, et al. A single cell atlas of human cornea that defines its development, limbal progenitor cells and their interactions with the immune cells. *Ocul Surf*. 2021;21:279-298.

39. Gupta S, Martin LM, Sinha NR, et al. Role of inhibitor of differentiation 3 gene in cellular differentiation of human corneal stromal fibroblasts. *Mol Vis*. 2020;26:742-756.

40. Espana EM, Kawakita T, Liu CY, Tseng SC. CD-34 expression by cultured human keratocytes is downregulated during myofibroblast differentiation induced by TGF-beta1. *Invest Ophthalmol Vis Sci*. 2004;45:2985-2991.

41. Beales MP, Funderburgh JL, Jester JV, Hassell JR. Proteoglycan synthesis by bovine keratocytes and corneal fibroblasts: maintenance of the keratocyte phenotype in culture. *Invest Ophthalmol Vis Sci*. 1999;40:1658-1663.

42. Tandon A, Tovey JC, Sharma A, Gupta R, Mohan RR. Role of transforming growth factor Beta in corneal function, biology and pathology. *Curr Mol Med*. 2010;10:565-578.

43. Jester JV, Petroff WM, Barry PA, Cavanagh HD. Expression of alpha-smooth muscle (α-SMA) actin during corneal stromal wound healing. *Invest Ophthalmol Vis Sci*. 1995;36:809-819.

44. Ljubimov AV, Saghirzadeh M. Progress in corneal wound healing. *Prog Retin Eye Res*. 2015;49:17-45.

45. Thieme D, Reuland L, Lindl T, Kruse F, Fuchsluger T. Optimized human platelet lysate as novel basis for a serum-, xeno-, and additive-free corneal endothelial cell and tissue culture. *J Tissue Eng Regen Med*. 2018;12:557-564.

46. Brejchova K, Trosan P, Stedynek P, et al. Characterization and comparison of human limbal explant cultures grown under defined and xeno-free conditions. *Exp Eye Res*. 2018;176:20-28.

47. Joyce NC, Meklir B, Joyce SJ, Zieske JD. Cell cycle protein expression and proliferative status in human corneal cells. *Invest Ophthalmol Vis Sci*. 1996;37:645-655.

48. Rudolph P, Peters J, Lorenz D, Schmidt D, Parwaresch R. Correlation between mitotic and Ki-67 labeling indices in paraffin-embedded carcinoma specimens. *Hum Pathol*. 1998;29:1216-1222.

49. Schroder R, Bien K, Kott R, Meyers I, Vossing R. The relationship between Ki-67 labeling and mitotic index in gliomas and meningomas: demonstration of the variability of the intermitotic cycle time. *Acta Neuropathol*. 1991;82:389-394.

50. Weidner N, Moore DH 2nd, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. *Hum Pathol*. 1994;25:337-342.

51. Liliensiek SJ, Campbell S, Nealey PF, Murphy CJ. The scale of substratum topographic features modulates proliferation of corneal epithelial cells and corneal fibroblasts. *J Biomed Mater Res A*. 2006;79:185-192.

52. Matthysen S, Ni Dhubhghaill S, Van Gerwen V, Zakaria N. Xeno-free cultivation of mesenchymal stem cells from the corneal stroma. *Invest Ophthalmol Vis Sci*. 2017;58:2659-2665.

53. Petroll WM, Miron-Mendoza M. Mechanical interactions and crosstalk between corneal keratocytes and the extracellular matrix. *Exp Eye Res*. 2015;133:49-57.

54. Jester JV, Barry-Lane PA, Cavanagh HD, Petroff WM. Induction of alpha-smooth muscle actin expression and myofibroblast transformation in cultured corneal keratocytes. *Cornea*. 1999;15:505-516.

55. Jester JV, Barry PA, Lind GJ, Petroff WM, Garana R, Cavanagh HD. Corneal keratocytes: in situ and in vitro organization of cytoskeletal contractile proteins. *Invest Ophthalmol Vis Sci*. 1994;35:730-743.

56. Jeon KL, Phipps RP, Sime PJ, Huxlin KR. Antifibrotic actions of peroxisome proliferator-activated receptor γ ligands in corneal fibroblasts are mediated by β-catenin-regulated pathways.

57. Kuriyan AE, Lehmann GM, Kulkarni AA, et al. Electrophilic PPARgamma ligands inhibit corneal fibroblast to myofibroblast differentiation in vitro: a potentially novel therapy for corneal scarring. *Exp Eye Res*. 2012;94:136-145.

58. Jester JV, Ho-Chang J. Modulation of cultured corneal keratocyte phenotype by growth factors/cytokines control in vitro contractility and extracellular matrix contraction. *Exp Eye Res*. 2003;77:581-592.

59. Miyagi H, Jalilian I, Murphy CJ, Thomsy SM. Modulation of human corneal stromal cell differentiation by hepatocyte growth factor and substrate compliance. *Exp Eye Res*. 2018;176:235-242.

60. Shukla MN, Rose JL, Ray R, Lathrop KL, Ray A, Ray P. Hepatocyte growth factor inhibits epithelial to myofibroblast transition in lungs via Smad7. *Am J Respir Cell Mol Biol*. 2009;40:643-653.

61. Malteva O, Folger P, Zekaria D, Petridou S, Masur SK. Fibroblast growth factor reversal of the corneal myofibroblast phenotype. *Exp Ophthalmol Vis Sci*. 2001;42:2490-2495.

62. Anitua E, de la Fuente M, Muruzabal F, Riestra A, Merayo-Lloves J, Orive G. Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts. *Exp Eye Res*. 2015;135:118-126.

63. Chaurasia SS, Kaur H, de Medeiros FW, Smith SD, Wilson SE. Dynamics of the expression of intermediate filaments vimentin and desmin during myofibroblast differentiation after corneal injury. *Exp Eye Res*. 2009;89:133-139.
65. Lassance L, Marino GK, Medeiros CS, Thangavadivel S, Wilson SE. Fibrocyte migration, differentiation and apoptosis during the corneal wound healing response to injury. Exp Eye Res. 2018;170:177-187.

66. Lipshitz I, Loewenstein A, Varssano D, Lazar M. Late onset corneal haze after photorefractive keratectomy for moderate and high myopia. Ophthalmology. 1997;104(3):369-374; discussion 373–364.

67. Medeiros CS, Saikia P, de Oliveira RC, Lassance L, Santiago MR, Wilson SE. Descemet’s membrane modulation of posterior corneal fibrosis. Invest Ophthalmol Vis Sci. 2019;60:1010-1020.

68. Marino GK, Santiago MR, Santhanam A, et al. Epithelial basement membrane injury and regeneration modulates corneal fibrosis after pseudomonas corneal ulcers in rabbits. Exp Eye Res. 2017;161:101-105.

69. Garrison G, Huang SK, Okunishi K, et al. Reversal of myofibroblast differentiation by prostaglandin E(2). Am J Respir Cell Mol Biol. 2013;48:550-558.

70. Hecker L, Jagirdar R, Jin T, Thannickal VJ. Reversible differentiation of myofibroblasts by MyoD. Exp Cell Res. 2011;317:1914-1921.

71. Burnouf T, Strunk D, Koh MB, Schallmoser K. Human platelet lysate: replacing fetal bovine serum as a gold standard for human cell propagation? Biomaterials. 2016;76:371-387.

72. Zhang J, Crimmins D, Faed JM, Flanagan P, McGhee CNJ, Patel DV. Characteristics of platelet lysate compared to autologous and allogeneic serum eye drops. Transl Vis Sci Technol. 2020;9:24.

73. Rauch C, Feifel E, Amann EM, et al. Alternatives to the use of fetal bovine serum: human platelet lysates as a serum substitute in cell culture media. AlTEX. 2011;28:305-316.

74. Shichinohe H, Kuroda S, Sugiyama T, et al. Biological features of human bone marrow stromal cells (hBMSC) cultured with animal protein-free medium-safety and efficacy of clinical use for neurotransplantation. Transl Stroke Res. 2011;2:307-315.

75. Gstraunthaler G, Zell- LT. Zell- und Gewebekultur allgemeine Grundlagen und spezielle Anwendungen. 7. Aufl. ed. [u.a.]. Springer Spektrum; 2013.

76. Schallmoser K, Bartmann C, Rohde E, et al. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion. 2007;47:1436-1446.

77. Mojica-Henshaw MP, Jacobson P, Morris J, et al. Serum-converted platelet lysate can substitute for fetal bovine serum in human mesenchymal stromal cell cultures. Cytotherapy. 2013;15:1458-1468.

78. Mohamed HE, Asker ME, Kotb NS, El Habab AM. Human platelet lysate efficiency, stability, and optimal heparin concentration required in culture of mammalian cells. Blood Res. 2020;55:35-43.

79. Freshney RI. Culture of animal cells a manual of basic technique, 5th ed. [u.a.]. Wiley-Liss; 2005.

Supporting Information
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Seidelmann N, Duarte Campos DF, Rohde M, et al. Human platelet lysate as a replacement for fetal bovine serum in human corneal keratocyte and fibroblast culture. J Cell Mol Med. 2021;25:9647-9659. https://doi.org/10.1111/jcmm.16912